GlassScriptPhysician profile
Debby Carl
NPI 1891147104
$3,529.52
in general payments reported to CMS, 2019-2025
25 companies · $760 in 2025
The $760 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $833 · 2022: $462 · 2023: $616 · 2024: $858 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,234.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $729.99 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $453.50 | 2021-2025 | Farxiga, Breztri, Bevespi Aerosphere |
| Otsuka America Pharmaceutical, INC. | $448.35 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Novo Nordisk INC | $383.68 | 2021-2025 | Ozempic, Rybelsus |
| Neurocrine Biosciences, INC. | $281.87 | 2024-2025 | Ingrezza |
| Glaxosmithkline, LLC. | $260.49 | 2021-2022 | |
| Indivior INC. | $197.86 | 2021-2023 | Sublocade |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.22 | 2021-2025 | Jardiance |
| Grifols USA, LLC | $72.34 | 2022-2025 | Prolastin-C Liquid |
| Dexcom, INC. | $71.94 | 2022-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $65.58 | 2023-2024 | Mounjaro, Zepbound, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.68 | 2024-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.02 | 2024-2025 | Caplyta |
| Insulet Corporation | $46.62 | 2025 | Omnipod |
| Lundbeck LLC | $44.36 | 2024-2025 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $42.57 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $37.67 | 2025 | Cobenfy |
| Abbott Laboratories | $34.50 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.19 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $30.71 | 2021-2024 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $26.48 | 2021 | |
| Globus Medical, INC. | $18.97 | 2025 | Senza |
| Electromed, INC. | $13.89 | 2025 | Smartvest |
| Merck Sharp & Dohme LLC | $13.41 | 2021 | |
| Amgen INC. | $12.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debby Carl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.